Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Frontiers in Digital Health
|
October 20, 2025
From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool
Dirk Schriefer, Anja Dillenseger, Yassin Atta, et al.
Biomedicines
|
March 29, 2023
Countermovement Jumps Detect Subtle Motor Deficits in People with Multiple Sclerosis below the Clinical Threshold
Anne Geßner, Heidi Stölzer-Hutsch, Katrin Trentzsch, et al.
Scientific Reports
|
September 17, 2025
Phenotyping and characterising gait profiles of people with multiple sclerosis
Katrin Trentzsch, Dirk Schriefer, Heidi Stölzer-Hutsch, et al.
Pharmacoeconomics
|
May 5, 2020
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Pharmacoeconomics
|
May 15, 2020
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Preventive Medicine Reports
|
February 18, 2017
Participation in preventive health check-ups among 19,351 women in Germany
Stefanie Schülein, Katherine J Taylor, Dirk Schriefer, et al.
Plos One
|
July 14, 2021
Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study
Luana F Tanaka, Dirk Schriefer, Kathrin Radde, et al.
Biomedicines
|
May 25, 2024
The Association of Age, Sex, and BMI on Lower Limb Neuromuscular and Muscle Mechanical Function in People with Multiple Sclerosis
Anne Geßner, Maximilian Hartmann, Katrin Trentzsch, et al.
Journal of Neurology
|
December 19, 2019
Differentiating societal costs of disability worsening in multiple sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neurology
|
January 17, 2025
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study
Hernan Inojosa, Dirk Schriefer, Nils-Henning Ness, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Frontiers in Digital Health
|
October 20, 2025
From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool
Dirk Schriefer, Anja Dillenseger, Yassin Atta, et al.
Biomedicines
|
March 29, 2023
Countermovement Jumps Detect Subtle Motor Deficits in People with Multiple Sclerosis below the Clinical Threshold
Anne Geßner, Heidi Stölzer-Hutsch, Katrin Trentzsch, et al.
Scientific Reports
|
September 17, 2025
Phenotyping and characterising gait profiles of people with multiple sclerosis
Katrin Trentzsch, Dirk Schriefer, Heidi Stölzer-Hutsch, et al.
Pharmacoeconomics
|
May 5, 2020
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Pharmacoeconomics
|
May 15, 2020
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Preventive Medicine Reports
|
February 18, 2017
Participation in preventive health check-ups among 19,351 women in Germany
Stefanie Schülein, Katherine J Taylor, Dirk Schriefer, et al.
Plos One
|
July 14, 2021
Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study
Luana F Tanaka, Dirk Schriefer, Kathrin Radde, et al.
Biomedicines
|
May 25, 2024
The Association of Age, Sex, and BMI on Lower Limb Neuromuscular and Muscle Mechanical Function in People with Multiple Sclerosis
Anne Geßner, Maximilian Hartmann, Katrin Trentzsch, et al.
Journal of Neurology
|
December 19, 2019
Differentiating societal costs of disability worsening in multiple sclerosis
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neurology
|
January 17, 2025
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study
Hernan Inojosa, Dirk Schriefer, Nils-Henning Ness, et al.
Page
of 4